In the human body, 50 billion to 70 billion cells die every day to make room for an equivalent number of new cells that are produced through cell division. Every year, the human body produces and kills a mass of cells equal to its entire body weight.
Scientists are studying apopsotis, a sort of "suicide mechanism" that instructs cells when it is time to die. Researchers are finding that a growing number of diseases occur when the regulation of this cell suicide program is defective.
San Diego-based Conatus Pharmaceuticals (CNAT) is at the forefront of studying the role of apoptosis in liver disease, The 150M market cap biotechnology company is focused on the development of emricasan.
There are many positives about the company. Conatus has an experienced and highly competent management team. The company has identified target markets that could not only prove to be very lucrative, but also serve a significant unmet need. Emricasan has demonstrated promising results in several studies, and could prove to be an effective treatment for not only liver disease, but also diabetes.
What I don't like about Conatus is that the company is dependent on the success of a single drug candidate. Emricasan must undergo significant additional clinical testing before the company can seek regulatory approval for the drug. In the event that emricasan succeeds in these trials, Conatus could be a big ticket buy for a larger pharmaceutical company. If emricasan fails, I do not think the company could recover. I have seen too many drugs that had stellar results in early and mid-stage trials fail in advanced studies due to a lack of safety or efficacy.
Conatus was founded by the executive management team of Idun Pharmaceuticals following the sale of Idun to Pfizer, Inc. (PFE) in July 2005. Conatus is led by Steven J. Mento, Ph.D., who is one of the company's co-founders and serves as its President and Chief Executive Officer (CEO). Mento was also the President and CEO of Idun Pharmaceuticals from 1997 to 2005.
Idun Pharmaceuticals was a private biotechnology company pioneering the development of drugs that target apoptosis (mediated cell death) in diseases related to cancer and inflammation.
Apoptosis plays an important role in the development and stability of all multi-cellular organisms. In humans, both excessive and insufficient apoptosis can result in severe pathological consequences. Excessive cell death is associated with stroke, heart failure, Alzheimer's disease, Parkinson's disease and acquired immune deficiency syndrome (AIDS). Too little cell death (cell accumulation) can cause cancer.
Caspases are the key agent that cause apoptosis. They exist in most of our cells as inactive precursors, known as zymogens, that kill the cell once it is activated. Capsase inhibition is being studied as a treatment for acute and chronic diseases of the heart, liver and nervous system, as well as autoimmune and infectious diseases. During its heyday, Idun was years ahead of the competition in capsase inhibition research. Today, a growing numer of companies are developing capsase inhibitors, including Gilead Sciences (GILD), Merck (MRK) and Sunesis Pharmaceuticals (SNSS).
In 1993, two highly respected scientists researching apoptosis, Robert Horvitz, a Massachusetts Institute of Technology biology professor, and John C. Reed, the scientific director of the Burnham Institute, founded Idun with Larry Bock and Lawrence Fritz, after big pharmaceutical companies rejected apoptosis technologies as too risky. While Horvitz's expertise focused on the development of drugs to stop the death of cells due to injury or disease, Reed's specialty involved developing drugs that expedited the death of cancer cells.
In 2002, Horvitz won the 2002 Nobel Prize in medicine/physiology for "discoveries concerning genetic regulation of organ development and programmed cell death." For many investors, the Nobel Prize validated the Idun's credibility and raised expectations about its pipeline.
The Conatus management team is comprised of former senior Idun executives, and its Chief Medical Officer was the clinical program leader for emricasan during its development at Pfizer. At Idun, these senior executives discovered and led the development of emricasan, which was also Idun's lead asset, until the company was sold to Pfizer for approximately $298 million.
Why did Pfizer buy Idun?
"The acquisition of Idun is a further step in our strategy to augment Pfizer's internal research and development efforts with high-potential, externally sourced product candidates and technologies," said Martin Mackay, Senior Vice President Worldwide Research and Technology for Pfizer. "Idun has built a leading technology platform in controlling caspase activity and we see potential broad application of this technology in treating liver damage associated with viral and non-viral diseases plus other areas of significant unmet medical need."
In July 2010, Conatus acquired the Pfizer subsidiary, Idun Pharmaceuticals, along with global rights to emricasan for an undisclosed sum.
Five years later, why did Pfizer sell Idun?
When Conatus acquired emricasan from Pfizer in 2010, emricasan was on clinical hold in the United States after Pfizer scientists observed inflammatory infiltrates in mice in a preclinical study of the investigational drug. They reported the infiltrates to the US Food and Drug Administration (FDA) in 2007. The agency placed a clinical hold on emricasan.
Pfizer performed additional preclinical studies attempting to characterize the nature of the infiltrates, but did not conduct a formal carcinogenicity study to evaluate whether or not the infiltrates progressed to cancer. These infiltrates, observed in mice, were not observed in any other species. In 2008, Pfizer stopped work on the program.
After acquiring emricasan, Conatus conducted a thorough internal review of emricasan studies, commissioned several independent experts to review the data and, based on guidance from the FDA, conducted a 6-month carcinogenicity study in the Tg.rasH2 transgenic mouse model, which is known to be predisposed toward tumor development. This study, which was completed in 2012, found there was no evidence of drug-related tumorgenicity in emricasan. After further discussions with the FDA, Conatus was cleared in January 2013 to proceed with its planned HCV-POLT trial, whuch formally lifted emricasan from clinical hold in the United States. Emricasan was never placed on clinical hold outside the United States.
Prior to its acquisition of emricasan, the company's lead program was CTS-1027, an oral small molecule hepatitis C investigational drug, that Conatus licensed from Hoffmann-La Roche (RHHBY.OB) in 2006. On October 25, 2011, Conatus announced the termination of its Phase 2 clinical trial of CTS-1027 in hepatitis C patients due to laboratory abnormalities and adverse events in a subset of clinical trial participants. In early 2012, the rights to this drug candidate reverted to Roche. Conatus spent $31.3 million to develop the drug.
Emricasan is a first-in-class, orally active caspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death. Conatus believes that by reducing the activity of these enzymes, emricasan has the potential to interrupt the progression of liver disease.
At both Idun and Pfizer, emricasan was being developed for the treatment of liver fibrosis. As a result of their collective experience, Conatus' executive management team believes it can successfully develop emricasan.
Emricasan has been administered to over 500 subjects in six Phase 1 and four Phase 2 clinical trials, and has been generally well-tolerated in both healthy volunteers and patients with liver disease. Emricasan has also been extensively profiled in in vitro tests and studied in many preclinical models of human disease.
Several Phase 1 clinical trials to assess safety, tolerability and pharmacokinetics of emricasan have been completed. One trial studied the IV formulation of the drug and five of the oral trials investigated the formulation. In its clinical summary of emricasan, Conatus reports that " emricasan was well tolerated, and a maximum tolerated dose was not identified." Emricasan did not reduce liver enzyme levels in normal volunteers. However, emricasan administration in liver impaired patients resulted in reductions in liver enzyme levels alanine transaminase (ALT) and aspartate transaminase (AST).
Conatus has designed a comprehensive clinical program to demonstrate the therapeutic benefit of emricasan across the spectrum of fibrotic liver disease. The company plans to study emricasan in patients with rapidly progressing fibrosis, such as those patients who have developed liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT), as well as in patients with established liver cirrhosis and decompensated disease, such as those with acute-on-chronic liver failure (ACLF) and chronic liver failure. (CLF).
Emricasan has been found to have a beneficial effect on serological biomarkers in patients with chronic liver disease independent of the cause of disease. Favorable changes have been observed in functional biomarkers of liver damage and inflammation, such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and mechanistic biomarkers, such as cleaved Cytokeratin 18 (cCK18) and caspase activity, indicating that emricasan works by the presumed mechanism of action of inhibiting apoptosis of liver cells. Researchers have also found that emricasan does not inhibit normal levels of caspase activity in healthy individuals.
Emricasan Development Strategy
The company's initial development strategy targets indications for emricasan with high unmet clinical need in orphan patient populations, such as patients with:
- acute-on-chronic liver failure (ACLF),
- chronic liver failure (CLF), and
- patients who have developed liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT).
Conatus expects to initiate a Phase 2b ACLF trial and a Phase 3 HCV-POLT trial, which is currently designated a Phase 3 registration study in the European Union (EU) and a Phase 2b study in the United States in the second half of 2013 and a Phase 2b CLF trial in the second half of 2014.
The US National Institutes of Health (NIH) estimates that 5.5 million Americans have chronic liver disease or cirrhosis. Liver disease is the 12th leading cause of death in the United States. According to the European Association for the Study of the Liver, 29 million Europeans have chronic liver disease.
According to the US Centers for Disease Control and Prevention (CDC), there were 101,000 discharges with chronic liver disease and cirrhosis as the first-listed diagnosis in the United States in 2010, and nearly 32,000 died as a result of these disorders.
In the United States, more than 5,000 liver transplants are performed in adults and more than 500 in children annually, with approximately 17,000 people awaiting transplant. Conatus plans to study the effectiveness of emricasan in defined subsets of patients with liver disease. ACLF, CLF and HCV-POLT are potential orphan indications in both the United States and European Union (EU).
Conatus estimates that the target populations for emricasan in these indications in the United States and the EU are approximately 150,000 ACLF patients, 10,000 CLF patients and 50,000 HCV-POLT patients.
Conatus originally applied for orphan drug designation for emricasan for the treatment of fibrosis in HCV-POLT patients in the United States and the EU. The company has not received the requested orphan designation from the FDA. In the EU, Conatus withdrew the application based on feedback that emricasan may have efficacy in fibrosis outside of the HCV-POLT patient population.
According to Transparency Market Research, the global liver diseases therapeutics market was worth $6.5 billion in 2011 and is expected to reach $10.9 billion in 2018, growing at a compound annual growth rate (CAGR) of 8.6% from 2012 to 2018.
Transparency researchers found that the major drivers of the global liver disease therapeutics market are increasing aging population inducing chronic diseases such as hepatitis and liver cancer, increasing global prevalence of liver disorder, high unmet needs existing in liver cancer and increased vaccination in emerging economies. However side effects and risks associated with the medication, strict FDA approval norms and other government regulations and availability of alternate treatment procedures may act as the barrier for this market. Strong pipeline drugs and consolidation opportunities in the healthcare industry will pose future growth prospect for this market.
Acute-on-Chronic Liver Failure
In recent years, acute-on-chronic liver failure (ACLF) has been recognized as a specific clinical form of liver failure associated with cirrhosis. The syndrome refers to an acute deterioration of liver function and subsequently of other organs over a period of weeks. The short-term mortality for this condition is more than 50%.
Fibrosis, if allowed to progress, usually leads to cirrhosis, or excessive scarring of the liver, which may result in reduced liver function. Some patients with liver cirrhosis have a partially functioning liver and may appear asymptomatic for long periods of time. This condition is compensated liver disease. In decompensated liver disease, the liver is unable to perform its normal functions. ACLF occurs in patients who have compensated or decompensated cirrhosis, but are in relatively stable condition until an acute event causes a rapid exacerbation of liver function.
Among liver diseases, cirrhosis is the most frequent reason for hospital admission or liver transplantation. The World Health Organization (WHO) projects that cirrhosis will become the ninth most common cause of death in the western world by 2015. Only 20% of patients with advanced cirrhosis globally can be treated with liver transplantation owing to the great imbalance between donation and potential recipients.
According to the research and advisory firm, GlobalData, the global liver cirrhosis market was estimated to be valued at $1.56 billion in 2010. GlobalData expects this market to grow to $2.03 billion with a CAGR of 3.8% by 2017. This growth is primarily attributed to the increasing prevalence of the disease due to increase in alcoholic liver disease, nonalcoholic steatohepatitis (NASH) and the large group of patients who were originally infected with hepatitis virus, who will be entering their third decade of chronic liver infection.
On September 11, 2013, Conatus announced the initiation of active patient recruitment in a Phase 2b clinical trial of emricasan in patients with ACLF. The trial is designed to assess the pharmacokinetics and pharmacodynamics of emricasan in patients who have compensated or stable liver cirrhosis and who, at the time of study entry have been hospitalized for at least 24 hours due to acute deterioration of liver function.
"This study marks an important milestone in the development of emricasan and we are excited about the potential of emricasan to address this underserved population in high medical need of an efficacious and well-tolerated therapy to prevent progression to multi-organ failure and, ultimately, premature death," said Gary C. Burgess, MD, Chief Medical Officer of Conatus.
Conatus plans to use this trial to determine the dose of emricasan to be studied in the planned Phase 3 trial in ACLF. Safety of emricasan in the patient population will be evaluated, and key biomarkers and clinical outcomes will also be explored. The Phase 2b trial is being conducted at approximately 15 centers in the United Kingdom.
There are currently no approved therapies with a specific indication for the treatment of ACLF, which occurs in patients who have compensated or decompensated cirrhosis but are usually relatively stable. In these patients, some acute event sets off a rapid deterioration of liver function. The cause of this acute episode of decompensation may include toxins, such as alcohol, metabolic abnormalities and infections.
The morbidity and mortality of the patient population Conatus plans to study is high, and up to 45% of the patients may die, develop multi-organ failure, or require a liver transplant as a result of the decompensation episode within 28 days of hospitalization. The rapid deterioration in liver function, which may be exacerbated by an altered immune response, leads to life-threatening complications such as renal failure, increased susceptibility to infection, hepatic coma and systemic hemodynamic dysfunction. Liver transplantation is required in some subjects to improve survival and quality of life.
In addition to the Phase 2b trial in patients with ACLF, Conatus expects to initiate its planned Phase 2b/3 clinical trial of emricasan in patients who have developed liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT) in the second half of 2013.
Chronic Liver Failure
Patients with chronic liver failure (CLF) suffer from continual disease progression may eventually need orthotopic liver transplantation. In 2004, liver failure resulted in over 26,000 deaths, making it the twelfth leading cause of death in the United States. Patients with compensated chronic liver failure have a median survival of 12 years. After decompensation, median survival drops to ~ 2 years.
Conatus plans to initiate a Phase 2b study comprised of approximately 100 patients with CLF in the second half of 2014 after completion of the ACLF Phase 2b trial. Conatus expects that emricasan will be dosed for one to three months and the endpoints in this study will include TTCW as well as changes in ALT, AST and cCK18 levels. The data from the ACLF dose ranging study is expected to serve as the basis for dose selection in this study.
Study A8491003, also known as the "003 trial," was a Phase 2b trial designed to evaluate the safety and efficacy of emricasan in 204 chronic HCV patients who were unresponsive to antiviral therapy and who had compensated liver disease with or without fibrosis. Patients with cirrhosis or hepatocellular carcinoma were excluded from the trial.
The primary endpoint in the study was changed from baseline in ALT and AST levels over a period of 12 weeks. This study also measured cCK18 levels, and caspase 3 and 7 activity as exploratory biomarkers. In this trial, emricasan treatment resulted in statistically significant reductions in the primary endpoints of ALT and AST levels as well as statistically significant reductions in cCK18 levels and caspase 3 and 7 activity.
The changes in ALT demonstrated in the 003 trial were statistically significant in each of the emricasan treatment groups compared with the placebo group. The decreases in ALT were seen by day 7, the first time post-dosing that ALT was measured, and the decreases were maintained throughout the treatment period (up to 12 weeks) in all emricasan treatment groups. Discontinuation of emricasan at the end of the treatment period was followed by a gradual return of ALT toward baseline levels.
A Phase 2a clinical trial of an oral formulation of emricasan was completed in patients infected with hepatitis C virus (HCV), most of whom had failed existing approved treatments. Various doses and dosing regimens ranging from 25 milligrams to 200 milligrams once a day, and 50 to 100 milligrams twice a day (BID) were examined during a two-week dosing period. The study found that all doses of the drug lowered ALT and AST by the end of the treatment period and were well tolerated.
Similar results were obtained in a trial which dosed patients for three months.
A small group of patients with fatty liver disease and a group with hepatitis B virus (HBV) were evaluated as supplemental cohorts of the Phase 2a HCV clinical trial. Aminotransferase reductions were observed during treatment with emricasan in both groups.
A Phase 2 trial was conducted to assess the utility of emricasan on cold ischemia/warm reperfusion (CI/W) injury during human liver transplantation. Researchers found that when emricasan was administered in cold storage and flush solutions during liver transplantation, offered local protection against CI/WR-mediated apoptosis and injury, but this was not observed when emricasan was administered to the patient. No safety signals of concern were seen in the study and the adverse events were generally reflective of the patient population under study.
In a randomized Phase 2b clinical trial in patients with liver disease, emricasan demonstrated a statistically significant, consistent, rapid and sustained reduction in elevated levels of two key biomarkers of inflammation and cell death, ALT and cCK18, both of which are implicated in the severity and progression of liver disease.
Conatus is planning to study emricasan in a 260-patient, Phase 3 HCV-POLT trial, which is currently designated a Phase 3 registration study in the European Union and a Phase 2b study in the United States during the second half of 2013, as well as a Phase 2b CLF trial in the second half of 2014.
The study is designed to demonstrate emricasan's ability to stabilize or slow the progression of liver fibrosis. If emricasan demonstrates the ability to halt the progression of fibrosis, Conatus believes this data could serve as a basis to study emricasan in additional indications in liver disease in the future. In addition, the safety data from this study will be part of the overall safety database required for approval of emricasan in other indications.
The study will be a two-year dosing study with a three-year follow-up. The primary endpoint will be the presence or absence of disease progression as measured by the standard Ishak Fibrosis Score, which stages the severity of fibrosis and/or cirrhosis on a 0-6 scale. Changes in ALT, AST and cCK18 will also be measured in this study.
If the results of clinical trials are positive and emricasan receives FDA or another country's approval, Conatus anticipates that emricasan would be prescribed by physicians to be dosed for 28 days, but potentially as long as six months, in the ACLF patient population, one to three months in the CLF patient population and up to two years in the HCV-POLT patient population.
Severe Alcoholic Hepatitis
On September 10, 2013, Conatus announced initiation of dosing in the Phase 2 clinical trial of emricasan in patients with severe alcoholic hepatitis. This study is being conducted by the Translational Research and Evolving Alcoholic Hepatitis Treatment (TREAT) Consortium consisting of the Mayo Clinic Rochester, Indiana University, and Virginia Commonwealth University in collaboration with the National Institute on Alcohol Abuse and Alcoholism (NIAAA).
"We are very excited by this trial initiation of emricasan in patients with severe alcoholic hepatitis," Conatus President and CEO Mento stated. "We are developing emricasan as a first-in-class orally active treatment for chronic liver disease and acute exacerbations of chronic liver disease. Due to emricasan's mechanism of action and the presence of apoptosis and inflammation in many liver diseases, we believe there may be several patient populations that could potentially benefit from emricasan and have designed a comprehensive clinical program to demonstrate the therapeutic benefit of emricasan across the spectrum of fibrotic liver disease."
The trial is a placebo-controlled, double-blind, multi-center study that is designed to assess whether emricasan improves the 28-day survival in patients with chronic liver disease caused by alcohol and contraindicated to receive corticosteroid therapy for their alcoholic hepatitis. The study is designed to also evaluate the role of apoptosis and sterile necrosis in alcoholic hepatitis, the safety and tolerability of emricasan, overall clinical outcomes, and pharmacokinetics in this patient population.
"We are looking forward to studying the potential beneficial effects of emricasan in patients afflicted by this severe disease," said Vijay Shah, MD, a hepatologist and principal investigator with the Mayo Clinic Rochester. "Alcohol-related liver disease is a major cause of morbidity and mortality in the U.S. and excessive alcohol consumption is the third leading preventable cause of death in the U.S."
In the United States, alcoholic liver disease affects more than 2 million people, representing approximately 1% of the population. The true prevalence of alcoholic hepatitis, especially of its milder forms, is unknown, because patients may be asymptomatic and never seek medical attention. Women are more susceptible than men to the adverse effects of alcohol. Women develop alcoholic hepatitis after a shorter period and smaller amounts of alcohol abuse than men, and alcoholic hepatitis progresses more rapidly in women than in men. For patients who continue to drink after a diagnosis of alcoholic liver disease, the 5-year survival rate is approximately 30% for women compared with 70% for men.
Alcoholic liver disease encompasses a clinical/histological spectrum of disease including fatty liver, alcoholic hepatitis and cirrhosis. Alcoholic hepatitis is a syndrome of progressive inflammatory liver injury associated with long-term heavy intake of ethanol. Severely affected patients show signs of retaining large amounts of fluid in the abdominal cavity (ascites), as well as kidney and liver failure.
Type 1 Diabetes
In addition to liver disease, emricasan may also show promise in diabetes.
On July 19, 2012, Conatus and the University of Alberta announced the treatment of the first patient in an investigator-initiated islet cell transplant Phase 1/Phase 2 clinical trial of emricasan to determine safety, achievement and maintenance of insulin independence and to obtain preliminary data on the efficacy of emricasan to maintain adequate immunological protection against both allo- and autoimmunity of islet cell transplant recipients.
Islet cell transplantation places cells from an organ donor into the body of another person. It is used experimentally to treat type 1 diabetes. Islets are cells found in clusters throughout the pancreas.
In type 1 diabetes, the beta cells of the pancreas no longer make insulin. A person who has type 1 diabetes must take insulin daily to live. Transplanted islet cells, however, can assume the work of the destroyed cells. Once they are implanted, the beta cells in these islets begin to make and release insulin. Researchers hope islet transplantation will help people with type 1 diabetes live without daily insulin injections.
Over 750 islet transplantations are conducted each year in 30 centers worldwide. Diabetologists, funding organizations and regulatory agencies recognize islet transplantation as an effective therapy to prevent episodic hypoglycemia, correct glycated hemoglobin and reduce risk of secondary diabetic complication.
"As Conatus pursues the development of emricasan on our own in liver disease, I am pleased to support new treatment paradigms in diabetes. If the results in humans are similar to the preclinical data, many more patients will benefit from islet cell transplantation," Conatus CEO Mento stated.
The trial will be conducted in two sequential pilot study groups of six patients each with two different dosages of emricasan for 14 days. Once optimal dosing has been determined from these pilot studies, the next proposed study would be a randomized, placebo-controlled study to explore the safety and efficacy of emricasan combined with other islet transplant treatment medications.
On September 9, 2013, Conatus announced financial results for the quarter ended June 30, 2013.
The net loss for the second quarter of 2013 was $4.9 million, compared to $1.8 million for the second quarter of 2012. Net loss for the six months ended June 30, 2013, was $7.2 million compared to $3.7 million for the comparable period in 2012.
Research and development expenses were $1.1 million for each of the second quarter of 2013 and 2012. General and administrative expenses were $0.7 million for the second quarter of 2013, compared to $0.6 million for the second quarter of 2012. Research and development expenses were $2.1 million for the six months ended June 30, 2013, compared to $2.3 million for the comparable period in 2012. General and administrative expenses were $1.4 million for each of the six months ended June 30, 2013 and 2012.
At June 30, 2013, cash, cash equivalents and short-term investments were $3.5 million, compared to $8.0 million at December 31, 2012. After giving effect to the net proceeds from Conatus' initial public offering and borrowings under Conatus' credit facility, at June 30, 2013, pro forma cash, cash equivalents and short-term investments were $63.5 million.
Conatus believes the company has sufficient funds for operations for at least the next 18 months, including the completion of its planned Phase 2b ACLF trial, Phase 2b/3 HCV-POLT trial and Phase 2b CLF trial.
As of June 30, 2013, Conatus had an accumulated deficit of $66 million.
"Conatus has made significant progress in recent months, including our successful initial public offering, which generated approximately $59 million in net proceeds," Mento stated. "With our enhanced balance sheet, we are focused on further developing emricasan, our first-in-class, orally active treatment for chronic liver disease and acute exacerbations of chronic liver disease, in three orphan populations with high unmet medical need."
Mento continued, "We anticipate a number of important upcoming clinical development milestones. In the second half of this year, we expect to initiate our Phase 2b study of emricasan in patients with acute-on-chronic liver failure and our Phase 2b/3 study in patients who have developed liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection. Furthermore, we are supporting a Phase 2 study funded by National Institute on Alcohol Abuse and Alcoholism in patients with alcoholic hepatitis, with enrollment currently underway."
On July 25, 2013, the initial public offering (IPO) for Conatus opened for trading at $11.06 after pricing six million shares at $11. On its first day of trading, Conatus stock hit an all-time high of $11.24 before sliding to $9.50 at market close. Over 3.4 million shares were exchanged on that day.
Over the past three months, Conatus stock has been in the $9 per share range, until recently, when it climbed over $10.
Most analysts are optimistic about Conatus. On August 19, 2013, Sun Trust Robinson Humphrey initiated coverage of Conatus with a Buy rating and a $17 price target. JMP Securities began coverage with an Outperform rating. Stifel Nicolaus started coverage with a Buy rating and a $16 price target, Piper Jaffray initiated coverage with an Overweight rating and a $16 price target. Zacks gave Conatus a 3 Hold rating,
Major shareholders include entities affiliated with Aberdare Ventures 2,177,192 shares (13.9%), entities affiliated with Advent Private Equity 1,986,071 shares (12.7%), and Coöperative Gilde Healthcare II U.A 1,348,773 shares (8.6%).
Although there are currently no therapeutic products approved for the treatment of ACLF, CLF or HCV-POLT, Galectin Therapeutics (GALT), Ocera Therapeutics (OCRX) and others are developing potentially promising therapies. Researchers are also finding stem cell therapy effective in liver cirrhosis.
In April 2013, one of Idun's founders, John C. Reed, became the head of Roche's pharmaceutical research and early development group, where he will oversee research as well as early stage and middle stage clinical trials with a budget in the billions. Will Reed bring a cutting edge apoptosis and cell death research program to Roche? If so, how would such a program impact Conatus?
Some investors have lost much of their enthusiasm for caspase inhibitors, including emricasan, especially after Gilead Sciences' decision in April 2010 to terminate its Phase 2 clinical trial of GS 9450, an investigational caspase inhibitor, in patients with chronic hepatitis C due to reports of significant laboratory abnormalities and adverse events in a number of clinical study participants.
With positive results coming out of several middle stage trials, there is a lot to like about Conatus, What I don't like about the company is that it has only one drug in its pipeline. Although emricasan looks promising, there is always too much risk when one puts "all of one's eggs in one basket." I believe that idiom to be true if you are a small-time investor or a 150M market cap biopharmaceutical company.